| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
BPD-B-1,4-diene does not have a specific biological target in the traditional sense. It is a photosensitizer that, upon activation by light, generates reactive oxygen species (ROS), particularly singlet oxygen, which cause localized cell damage and death. One source indicates it is a potent activator of the G protein-coupled receptor and has been shown to bind to and activate the mu opioid receptor. It also inhibits ion channels such as Na+ currents in neurons and glutamate neural activity.
|
|---|---|
| ln Vitro |
In vitro, BPD-B-1,4-diene is used as a photosensitizer in photodynamic therapy research. Its activity is assessed by measuring its ability to generate reactive oxygen species upon light activation and its subsequent cytotoxic effects on cells. The compound's strong absorption in the near-infrared region allows for deeper tissue penetration, making it suitable for PDT applications. Its photosensitizing properties are characterized by its singlet oxygen quantum yield and its phototoxicity against cancer cells.
|
| ln Vivo |
In vivo, BPD-B-1,4-diene is not typically administered as a therapeutic agent. It is a research compound and a precursor to verteporfin, which is used clinically in PDT for the treatment of certain cancers and ocular diseases. The compound's photodynamic properties are evaluated in animal models of cancer, where it is administered systemically or locally, followed by light activation. Tumor regression and tissue damage are assessed.
|
| Enzyme Assay |
The in vitro activity of BPD-B-1,4-diene is assessed using photodynamic therapy assays. Cancer cells are cultured in appropriate media and treated with various concentrations of BPD-B-1,4-diene (typically 0.01-10 µM) for defined periods (1-24 hours). Cells are then irradiated with light at a specific wavelength (typically 690 nm) and energy dose. Cell viability is assessed using MTT or CellTiter-Glo assays 24-48 hours after light activation. The photosensitizing effect is evaluated by comparing cell viability with and without light activation. Reactive oxygen species (ROS) production can be measured using DCFH-DA fluorescence.
|
| Cell Assay |
For cellular assays, cancer cell lines (e.g., HeLa, A549, HT-29) are cultured in appropriate media. Cells are treated with various concentrations of BPD-B-1,4-diene for defined periods. Cells are then irradiated with light at 690 nm (typically 1-10 J/cm²). Cell viability is assessed using MTT or CellTiter-Glo assays. Apoptosis is evaluated by flow cytometry using Annexin V/PI staining. ROS production is measured using DCFH-DA fluorescence. The subcellular localization of the photosensitizer can be assessed by fluorescence microscopy.
|
| Animal Protocol |
In vivo, BPD-B-1,4-diene is typically administered intravenously to mice bearing tumor xenografts. The compound is formulated in a suitable vehicle (e.g., 5% DMSO, 40% PEG300, 5% Tween-80, and 50% ddH2O) and administered at various doses. After a defined drug-light interval (typically 1-24 hours), the tumor is irradiated with light at 690 nm. Tumor growth is monitored by measuring tumor volume. Tumor regression, necrosis, and apoptosis are assessed by histopathological examination.
|
| ADME/Pharmacokinetics |
BPD-B-1,4-diene has a molecular formula consistent with its benzoporphyrin structure. The compound is soluble in DMSO and should be stored as a powder at -20°C under desiccated conditions, protected from light. Specific pharmacokinetic parameters such as bioavailability, half-life, and volume of distribution are not detailed in the provided search results. The compound's strong absorption in the near-infrared region is a key property for its photosensitizing activity.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for BPD-B-1,4-diene is not available in the provided search results. As a photosensitizer, its toxicity is primarily related to light-activated ROS generation. The compound is intended for research purposes only and is not approved for human or veterinary use. Standard laboratory safety precautions should be followed when handling the compound. Comprehensive toxicological studies are required to establish its full safety profile.
|
| Additional Infomation |
BPD-B-1,4-diene is a research compound used in photodynamic therapy research. It is a precursor to verteporfin, a clinically approved photosensitizer used for the treatment of choroidal neovascularization and certain cancers. BPD-B-1,4-diene is used for making porphyrin-related dyes, nanoparticles, and other photodynamic therapeutic drugs. It is not approved for clinical use and is intended for research purposes only.
|
| Molecular Formula |
C42H44N4O8
|
|---|---|
| Molecular Weight |
732.820771217346
|
| CAS # |
94238-43-4
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3646 mL | 6.8230 mL | 13.6459 mL | |
| 5 mM | 0.2729 mL | 1.3646 mL | 2.7292 mL | |
| 10 mM | 0.1365 mL | 0.6823 mL | 1.3646 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
